Solna, Sweden, 7 March 2022 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, is pleased to announce a significant expansion of its intellectual property (IP) portfolio associated with its core drug delivery technology platform XR-17™.

XMeNa patents have been granted in Japan, Singapore, Russia and in several other jurisdictions, protecting an improved method for the manufacturing of the unique XR-17™ components.

The XMeNa patent adds to Oasmia’s broad IP portfolio and provides patent protection for the XR‑17™ technology and Oasmia’s lead product Apealea® (paclitaxel micellar) to 2036.

Apealea® is about to be commercialized in key markets around the world and is due to be launched in the UK and Germany in H1 2022. Oasmia is committed to expanding its intellectual property portfolio which covers its existing XR-17™ platform and future enhancements of the platform.

Reinhard Koenig M.D., Chief Scientific Officer of Oasmia, commented “The approval of these XMeNa patents provides protection for our XR-17™ technology platform in many key territories and also provides protection for our lead product Apealea® and Docetaxel Micellar in any future developments that will use the XR-17™ platform.”

In addition to these recently granted patents, the XMeNa patent is already approved in several major pharmaceutical markets including Europe, the US, India, and Australia.

For More Information: 

Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 

Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700 

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit